Vir Biotechnology Inc VIR

NAS: VIR | ISIN: US92764N1028   6/05/2024
10,22 USD (-1,64%)
(-1,64%)   6/05/2024

3 april 2023 · Marianne De Backer: 'Ik kreeg tientallen aanbiedingen, maar CEO van Vir Biotechnology is mijn droomjob’ · Tijd.be (€)

Na drie decennia aan de top bij bigpharmabedrijven als Bayer en J&J heeft Marianne De Backer sinds maandag voor het eerst de functie van CEO. Het beursgenoteerde Amerikaanse biotechbedrijf Vir Biotech...

10 november 2022 · Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm · Persbericht

30 maart 2022 · Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600 · Persbericht

4 november 2021 · Section 32 Raises $740 Million Venture Fund · Persbericht

29 maart 2021 · Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 · Persbericht

18 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR · Persbericht

11 maart 2021 · Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19 · Persbericht

25 februari 2021 · Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

17 februari 2021 · GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses · Persbericht

11 februari 2021 · Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 · Persbericht

1 februari 2021 · Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics · Persbericht

27 januari 2021 · Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 · Persbericht

12 januari 2021 · Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus · Persbericht

12 januari 2021 · Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 · Persbericht

Mijn selecties